PCGEM1 is a novel, highly prostate tissue-specific, androgen-regulated gene. Here, we demonstrate that PCGEM1 expression is significantly higher in prostate cancer (CaP) cells of African-American men than in Caucasian-American men (P ¼ 0.0002). Further, increased PCGEM1 expression associates with normal prostate epithelial cells of CaP patients with a family history of CaP (P ¼ 0.0400). PCGEM1 overexpression in LNCaP and in NIH3T3 cells promotes cell proliferation and a dramatic increase in colony formation, suggesting a biological role of PCGEM1 in cell growth regulation. Taken together, the cell proliferation/colony formationpromoting functions of PCGEM1 and the association of its increased expression with high-risk CaP patients suggest the potential roles of PCGEM1 in CaP onset/ progression, especially in these high-risk groups.
Introduction
Prostate cancer (CaP) is a complex, multifactorial disease with heterogeneous tumor types, making prediction of the clinical course for individual CaP patients a difficult challenge (Small, 1998; Isaacs et al., 2002) . Traditional prognostic markers, such as Gleason grade, clinical stage, and pretreatment prostate-specific antigen (PSA) levels have only limited prognostic value for an individual patient (Small, 1998) . The established risk factors for CaP are patient age, ethnic origin, and CaP family history . The molecular mechanisms of CaP susceptibility are being currently defined Xu et al., 2002) .
Among several approaches to define CaP-specific genetic alterations, comparison of global gene expression profiles in cancer cells and corresponding normal cells is emerging as a successful strategy, revealing consistent overexpression of HEPSIN (Dhanasekaran et al., 2001; Magee et al., 2001; Welsh et al., 2001; Luo et al., 2002) and AMACR in CaP, and EZH2 in metastatic CaP. Recently, the expression pattern of a group of five genes was reported to correlate with CaP progression (Singh et al., 2002) . Gene expression alterations in tumor cells may also predispose to cancer (Yan et al., 2002) . CaPspecific global gene expression analyses in our laboratory have defined PCGEM1 as a highly prostate-specific, androgen-regulated gene with cancer-associated overexpression .
PCGEM1 appears to be a noncoding functional RNA gene . PCGEM1 is similar to DD3 (Bussemakers et al., 1999) in that these genes are highly prostate-specific, nonprotein-coding genes. However, no sequence homology exists between PCGEM1 and DD3. Recent reviews of the literature (Szymanski and Barciszewski, 2002 ) and a database of noncoding RNAs demonstrate (http://biobases.ibch.poznan.pl/ ncRNA/) that an increasing number of noncoding RNA genes are being discovered that may have biological functions in diverse cellular processes. H19, His-1, and Bic represent examples of noncoding RNAs implicated in tumorigenesis (Szymanski and Barciszewski, 2002) . In this regard, PCGEM1 and DD3 may represent a new class of prostate-specific genes. Therefore, our laboratory is pursuing an in-depth evaluation of the biological functions of PCGEM1 and features of its tumor-associated expression.
In order to gain an insight into the cell biologic function of PCGEM1, NIH3T3 and LNCaP cells overexpressing PCGEM1 were generated. Cells were transfected with PCGEM1 cDNA cloned into a eucaryotic expression vector (pEAK8). Puromycinresistant transfectants were selected and pooled cell lines stably overexpressing PCGEM1 have been established. The strong expression of PCGEM1 RNA in both the LNCaP and the NIH3T3 transfectants was detectable by Northern blot analysis (Figures 1a and 2a Inset) . Control cells were transfected with the vector without the PCGEM1 insert.
The effects of PCGEM1 overexpression on cell growth/proliferation and cell cycle were evaluated. NIH 3T3 and LNCaP transfectants overexpressing PCGEM1 were plated at low density in 96-well plates. Cell growth was followed by either counting the cell number or by a colorimetric assay. Both LNCaP cells ( Figure 1a ) and NIH3T3 cells (Figure 2a ) overexpressing PCGEM1 exhibited a highly significant increase in proliferation compared to the vector-control-transfected cells (Po0.001, calculated by t-test). Further, in colonyforming assays with both LNCaP cells (Figure 1b ) and NIH3T3 cells (Figure 2b) , overexpression of PCGEM1 led to a dramatic increase in colony formation compared to the vector control.
The effect of PCGEM1 overexpression on cell cycle was analysed using a panel of phosphorylation-specific antibodies raised against key cell-cycle-related proteins in Western blot experiments (CDC2, CDC25, p53, Rb Ser780, Rb Ser795, Rb Ser807/811, cyclin D1, and Chk1). In both LNCaP ( Figure 1c ) and NIH 3T3 (Figure 2c ) cells overexpressing PCGEM1, a significant increase in Rb phosphorylation (Ser807/811) was detected, indicating that PCGEM1 overexpression may affect cell proliferation through Rb phosphorylation. Rb Ser807/811 is often phosphorylated in uveal melanoma, the most common malignancy of the eye, and Rb is functionally inactivated by this phosphorylation (Brantley and Harbour, 2000) . Rb Ser807/811 phosphorylation has been shown to disrupt Rb binding to the protooncogene c-abl (Knudsen and Wang, 1996) . Further experiments are needed to reveal the signal transduction pathway involving PCGEM1 and Rb Ser807/811.
The cell proliferation/colony formation-promoting effects of PCGEM1 overexpression in the LNCaP prostate cell line suggest that it may have a functional role in cell growth regulation in human CaP cells. Sequence analysis of mouse and rat genome sequences revealed a 131 bp region of strong homology to human PCGEM1 (83% to mouse, 85% to rat), which weakens (about 60%) with several gaps in the surrounding regions. The homology exists only at the DNA/RNA level; no possible peptides appear to be conserved between the different species. The PCGEM1 genomic sequence homology is between corresponding regions of human chromosome 2, mouse chromosome 1, and rat chromosome 9. RNA secondary structure prediction analysis (Mfold) indicated that PCGEM1 RNA has a lower free energy state than coding genes of the same size, or randomized versions of the PCGEM1 sequence. Within the 1.6 kb PCGEM1 cDNA, the first half (1-800 bp) had much lower predicted free energy (À221) than the second half (À163), indicating that the presence of a low-energy, stable secondary RNA structure is more likely in the first 800 bp region of PCGEM1. Mutational analysis of PCGEM1 as well as efforts to identify intracellular molecules binding to PCGEM1 RNA are in progress in our laboratory. A total of 1000 cells/well were plated in 96-well plates, and cell proliferation was measured each day for 7 days in triplicate for each cell line. P-values for data-point average pairs were determined by the t-test. The Po0.0001 value (shown in the figure) is reached by Day 6 and Day 7. For the colony formation assay, 3000 cells were plated in 100 mm Petri dishes or T-75 cell culture flasks for each cell line. After 2 weeks, the developing individual colonies were stained with crystal violet. The number of colonies formed after 2 weeks by LNCaP parent cells (250-280) and LNCaP cells overexpressing PCGEM1 (3000-3600) were counted in three independent experiments, and the average values were analysed by the t-test. The fulllength PCGEM1 cDNA was obtained in a eucaryotic expression vector (pEAK8, Edge BioSystems) by screening a prostate cDNA library (Edge BioSystems). A sequence-verified PCGEM1 cDNA gene in the pEAK8 expression vector was transfected into both LNCaP and NIH3T3 cells using lipofectamine (Invitrogen, Carlsbad, CA, USA). Transfectants were selected by 0.2 mg/l (LNCaP) or 5 mg/l (NIH3T3) puromycin (Edge BioSystems). (c) Detection of Rb phosphorylation in LNCaP cells with and without PCGEM1 expression. Protein lysates from exponentially growing cells were quantitated using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) and 30 mg aliquots were subjected to Western blotting. Antibodies raised against phosphorylated forms of cell cycle-related proteins CDC2, CDC25, p53, Rb Ser780, Rb Ser795 and Rb Ser807/811, Chk1, as well as the Rb control antibody, were obtained from Cell Signaling Technology (Beverly, MA, USA) PCGEM1 expression and function in prostate cancer G Petrovics et al
Although the number of noncoding RNA genes identified has sharply increased in recent years (http:// biobases.ibch.poznan.pl/ncRNA/), functional data are available only on a small subset of these genes (Szymanski and Barciszewski, 2002) . H19, one of the most well-characterized noncoding RNAs, exhibited tumor suppressor activity when overexpressed in embryonal carcinoma cells (Hao et al., 1993) . Recent results, however, indicated that in breast epithelial cells, H19 overexpression promotes tumor progression without affecting cell proliferation (Lottin et al., 2002) . His-1 (Askew et al., 1994) and Bic (Tam et al., 1997) are noncoding RNA genes whose transcription is activated by retroviral insertion, and they are implicated in the pathogenesis of hematological malignancies. Avian bic cooperates with c-myc in oncogenesis, and in enhancing the growth of chicken embryo fibroblasts (Tam et al., 2002) . No functional data are reported on the prostatespecific noncoding gene DD3, which has a highly CaPspecific expression (Bussemakers et al., 1999) .
In an attempt to assess potential clinical utility of PCGEM1, its expression levels in both cancer and normal prostate epithelial cells derived from radical prostatectomy specimens of CaP patients were analysed. Using OCT-embedded frozen sections of prostate tissues, prostate epithelial cells with normal and cancer phenotypes, as defined by hematoxylin-eosin (H&E) staining, were laser capture microdissected (LCM). A total of 180 RNA specimens representing microdissected paired normal and tumor cells of 90 CaP patients were quantified and used for expression analyses.
As a quality control, each LCM RNA sample was assayed by RT-PCR for the expression of NKX 3.1, a prostate epithelial cell marker . In a subset of 40 patients, the expression of DD3, a sensitive and specific marker of prostate tumor cells (DeKok et al., 2002) , was also determined. Over 80% of the patients exhibited higher DD3 expression in their prostate tumor cells than in the normal prostate epithelium (data not shown). This bank of paired normal and tumor cell-derived RNAs were screened by real-time multiplex quantitative RT-PCR (TaqMan) for the expression of PCGEM1. The expression data were normalized to GAPDH expression levels, which was measured in parallel in the same tubes (multiplex PCR).
The association of PCGEM1 expression data with 35 different clinicopathological parameters linked to the CaP patients were analysed (full list in legends to Table 1 ). A summary of PCGEM1 association with selected clinicopathological features is presented in Table 1 . The statistical analyses revealed a striking association between PCGEM1 expression levels and the ethnic origin of CaP patients. Tumor cells of AfricanAmerican CaP patients (n ¼ 22) harbored significantly higher PCGEM1 expression (P ¼ 0.0002) compared to those of Caucasian-American CaP patients (n ¼ 66) (Figure 3a) . In contrast, PCGEM1 expression in normal prostate epithelial cells of these two patient groups was not significantly different (P ¼ 0.6001) (Figure 3b ). In the African-American patient population, PCGEM1 expression was increased in their prostate tumor cells compared to matched normal prostate epithelial cells in 68.2% of the cases (15/22). On the other hand, 41% (27/ 66) of Caucasian-American CaP patients showed tumor cell-associated PCGEM1 overexpression in comparison to matched normal epithelial cells. To our knowledge, this is the first observation of a prostate-specific gene with a cell growth-promoting function that shows elevated expression in African-American CaP patients, the population with the highest CaP incidence in the world. At this point, however, we cannot conclude that PCGEM1 overexpression is cancer specific, because PCGEM1 expression has not been evaluated in other pathological conditions of the prostate (BPH, prostatitis). PCGEM1 expression and function in prostate cancer G Petrovics et al Genetic, hormonal, and environmental factors may contribute to a higher risk of CaP in African-American men (Brawley et al., 1998; Powell, 1998; Cussenot and Valeri, 2001 ). Polymorphism of genes, for example, CYP3A4 (Paris et al., 1999) , androgen receptor (Platz et al., 2000) , and vitamin D receptor (Taylor et al., RNA isolated (MicroRNA kit, Stratagene, La Jolla, CA, USA) from LCM samples of tumor and normal epithelial cells of radical prostatectomy patients were quantitated (RiboGreen dye, Molecular Probes, Eugene, OR and VersaFluor fluorimeter, BioRad, Hercules, CA, USA) and assayed by real-time quantitative RT-PCR (TaqMan). In all, 1 ng LCM RNA was used to produce cDNA, sufficient for 10 PCR reactions. Real-time quantitative PCR analysis was performed using TaqMan detection chemistry on the ABI Prism 7700 Sequence Detection System according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). PCR primers were: forward primer, 5 0 -TTCAATTAGGCAG CAACCTTT-3 0 ; reverse primer, 5 0 -CATTCAGCTCTATGAATCTGCTTAA-3 0 ; and Taqman probe, FAM-CCGTAACCTGTGTCTG CAACTTCCTCTAATT-TAMRA. Each PCR was multiplexed using the GAPDH detection control mix (Applied Biosystems, Foster City, CA, USA) as an internal control in the same tube with the PCGEM1 mix. GAPDH control cycle threshold (C T ) values obtained from the real-time PCR assays were subtracted from the PCGEM1 C T values. The resulting values represent PCGEM1 expression levels normalized to GAPDH (dC T values). Normalized PCGEM1 expression levels were categorized as 1 (dC T 410), 2 (6odC T o10), 3 (3odC T o6), 4 (1odC T o3), 5 (dC T o1), and 0 (no detectable PCGEM1 expression). Statistical analysis was performed with the SAS software package (SAS Institute Inc., Cary, NC, USA), comparing PCGEM1 expression categories 0-3 ('low' and no PCGEM1 expression) to categories 4-5 ('high' PCGEM1 expression). The association between PCGEM1 expression and clinicopathological features was analysed using Fisher's exact test. The number of patients is in brackets. Po0.05 was considered statistically significant. The prostate tissue specimens were obtained under an IRB-approved protocol from patients treated at Walter Reed Army Medical Center (WRAMC) and Uniformed Services University of the Health Sciences (USUHS). The patient database included the following clinicopathological parameters: race, prebiopsy PSA, diagnosis date, surgery date, age at surgery, left Gleason sum, right Gleason sum, worst Gleason sum, prostatitis at diagnosis, PIN, HGPIN, pretreatment testosterone, family history of CaP, T stage, neoadjuvant date, margins, tumor number; PSA recurrence: months after surgery, date, prostatitis pathology; bone metastasis: months after surgery, date; follow-up: months after surgery, latest contact date, capsule, seminal vesicle, nodes, worst grade, bladder neck, multifocal, diagnosis PSA, worst nuclear grade, prostate weight, hormone refractory date, differentiation at LCM microenvironment PCGEM1 expression and function in prostate cancer G Petrovics et al 1996), may predispose African-American men to higher CaP risk in comparison to Caucasian-Americans. Bcl-2, an antiapoptotic protein (Guo et al., 2000) and caveolin-1, a membrane protein with tumor suppressor activity (Yang et al., 2000) , show differential expression in CaP cells of African-American men compared to CaucasianAmericans. PCGEM1 belongs to this latter category, with several interesting features: it is a prostate-specific gene, it promotes cell proliferation/colony formation, and it shows highly significant prostate tumor cellspecific overexpression in African-Americans versus Caucasian-Americans. It is worth noting that increased PSA levels in the serum of African-American men compared to that of Caucasian-Americans have been described (Moul et al., 1995) . Although PCGEM1 is an androgen-regulated gene, we found no significant association between pretreatment PSA levels and PCGEM1 expression in either tumor (P ¼ 0.2031) or normal (P ¼ 0.6705) prostate epithelial cells (Table 1) , making it unlikely that a general induction of the androgen pathway would be responsible for the elevated PCGEM1 RNA levels.
Intriguingly, our analysis of the relative levels of PCGEM1 in histologically normal cells of CaP patients revealed a significant increase in PCGEM1 expression in patients with a family history of CaP (12/24), as Table 1 . The percentage of African-American (black columns) and Caucasian-American (striped columns) CaP patients expressing PCGEM1 at different levels (0-5) in their prostate epithelial cells are represented by the columns. The P-value (in box) was calculated by Fisher's exact test Figure 4 PCGEM1 expression in microdissected tumor (a) and normal (b) prostate epithelial cells of CaP patients with and without family history of CaP. PCGEM1 expression data were obtained and analysed as described in Table 1 . The percentage of patients with (black columns) and without (striped columns) a family history of CaP expressing PCGEM1 at different levels (0-5) in their prostate epithelial cells are represented by the columns. The P-value (in box) was calculated by Fisher's exact test opposed to patients with no family history (15/59) (P ¼ 0.0400) (Figure 4) .
A multivariable logistic regression analysis with backward elimination of insignificant variables was performed for the association of PCGEM1 expression with patient characteristics (race, family history of CaP, margin, prebiopsy PSA, prostate weight, worst Gleason sum, differentiation). The analysis revealed that the African-American race is significantly related to PCGEM1 expression in tumor cells (P ¼ 0.0007), and a family history of CaP is significantly related to PCGEM1 expression in normal prostate epithelial cells (P ¼ 0.0374). All other variables analysed were insignificant.
Potential CaP biomarkers that are consistently overexpressed in CaP cells, for example, HEPSIN, AMACR, DD3, and PSMA, do not show any reported association with ethnicity or family history of CaP . Loss of GSTP1 expression is also among the most common alterations in CaP cells (Nelson et al., 2001 ). PCGEM1 appears to be a distinct prostate-specific gene associated with these high-risk CaP patients. Only a few studies on cancer-associated expression of other noncoding RNA genes have been reported. H19 appears to be lost in certain embryonal tumors (Hao et al., 1993) , but overexpressed in a small subset of breast cancers (Lottin et al., 2002) . Retroviral insertion events appear to activate the expression of Bic (Tam et al., 1997) and of His-1 (Askew et al., 1994) , but cancer-associated expression of these genes in humans has not been reported. The expanding universe of noncoding RNAs and their functional evaluations may define additional genes with potential functions in the process of tumorigenesis.
Taken together, the cell proliferation/colony formation-promoting function of a novel prostate-specific noncoding gene, PCGEM1, and the association of its increased expression level with high-risk CaP patients suggest the potential roles of PCGEM1 in CaP biology. Further, PCGEM1 expression characteristics may provide a promising biomarker and potential therapeutic target in the high-risk CaP patients noted herein.
Abbreviations CaP, prostate cancer; PSA, prostate-specific antigen; FBS, fetal bovine serum; LCM, laser capture microdissection; RT, reverse transcription; H&E, hematoxylin-eosin.
